News for Alexion Pharmaceuticals, Inc. (0QZM.L)

On March 31, 2025, Camber Capital Management LLC (Trades, Portfolio) executed a significant reduction in its holdings of Brookdale Senior Living Inc. The firm d

**media[617621]**

PR NewswireTOKYO, May 7, 2025 TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today annou

**media[587758,587759]**

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, at...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines fo

On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a significant transaction by acquiring 2,722,987 shares of ZimVie Inc at a trad

On December 31, 2024, Camber Capital Management LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,197,987 shares of PTC Therapeutics Inc.

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and

Labcorp Holdings Inc. (LH) has announced a significant change in its executive leadership team. On November 15, 2024, Glenn Eisenberg, the company's Executive

An increase in the prevalence and misdiagnosis of rare diseases has led to an increase in the sales of orphan drugs....

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Visiongain has published a new report entitled Rare Diseases Market Report 2024-2034: Forecasts by Diseases (Cancer, Metabolic Diseases, Neurological...

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from...

Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial ...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Rapid development and innovation in light therapy technologies and growing patient’s preference toward non-invasive procedures are key factors driving...